

Screening of differentially expressed genes and identification of *NUF2* as a prognostic marker in breast cancer

WENJIE XU¹, YIZHEN WANG^{1,2}, YANAN WANG¹, SHANMEI LV^{1,2}, XIUPING XU¹ and XUEJUN DONG¹

¹Department of Clinical Laboratory Center, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing People's Hospital, Shaoxing, Zhejiang 312000; ²Zhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China

Received November 2, 2018; Accepted May 29, 2019

DOI: 10.3892/ijmm.2019.4239

Abstract. The aims of the present study were to screen differentially expressed genes (DEGs) in breast cancer (BC) and investigate NDC80 kinetochore complex component (*NUF2*) as a prognostic marker of BC in detail. A total of four BC microarray datasets, downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, were used to screen DEGs. A total of 190 DEGs with the same expression trends were identified in the 4 datasets, including 65 upregulated and 125 downregulated DEGs. Functional and pathway enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery. The upregulated DEGs were enriched for 10 Gene Ontology (GO) terms and 7 pathways, and the downregulated DEGs were enriched for 10 GO terms and 10 pathways. A protein-protein interaction network containing 149 nodes and 930 edges was constructed using the Search Tool for the Retrieval of Interacting Genes, and 2 functional modules were identified using the MCODE plugin of Cytoscape. Based on an in-depth analysis of module 1 and literature mining, *NUF2* was selected for further research. Oncomine database analysis and reverse transcription-quantitative PCR showed that *NUF2* is significantly upregulated in BC tissues. In analyses of correlations between *NUF2* and clinical pathological characteristics, *NUF2* was significantly associated with the malignant features of BC. Using 5 additional datasets from GEO, it was demonstrated that *NUF2* has a significant prognostic role in both ER-positive and ER-negative BC. A Gene Set Enrichment Analysis indicated that *NUF2* may regulate breast carcinogenesis and progression via cell cycle-related

pathways. The results of the present study demonstrated that *NUF2* is overexpressed in BC and is significantly associated with its multiple pathological features and prognosis.

Introduction

Breast cancer (BC) is the most common female malignancy and the second leading cause of mortality in women worldwide (1). According to the World Health Organization in 2012, one-third of Asian women develop BC (2,3). Currently, BC treatment includes partial excision with or without radiotherapy and systemic therapies such as endocrine therapy, chemotherapy, molecular targeted therapy, and a combination of them (4). Although advanced therapeutic techniques based on surgery have considerably improved the survival of patients with BC and the five-year survival has increased from 75% in 1976 to 91% in 2017, high rates of metastasis and recurrence remain (1,5,6). Recently, molecular targeted therapy has been shown to play an important role in individualized treatment of BC. For instance, a monoclonal antibody against HER2, trastuzumab, has been demonstrated to improve survival of patients with BC; however, the prognosis remains poor (7,8). Therefore, to improve BC prognosis, effective therapeutic targets and prognostic biomarkers are needed.

NDC80 kinetochore complex component (*NUF2*), also known as CDCA1, is a centromere-related protein (9). It regulates the binding of centromeres to spindle microtubules, participates in cell cycle regulation and has important roles in cell proliferation and apoptosis (10). *NUF2* is overexpressed in a number of cancers, including lung cancer, cholangiocarcinoma, renal cell carcinoma and bladder cancer (11). Although the expression and prognostic significance of *NUF2* in BC have been suggested (12,13), its precise role and underlying molecular mechanisms of action remain to be investigated.

In the present study, 4 mRNA microarray datasets were analyzed from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases to identify differentially expressed genes (DEGs) between BC tissues and normal breast tissues. The bioinformatics analysis and literature mining suggested that *NUF2* is a key gene in the progression of BC. The expression of *NUF2* in BC samples and its correlation with clinical pathological characteristics

Correspondence to: Professor Xuejun Dong, Department of Clinical Laboratory Center, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing People's Hospital, 568 Zhongxing North Road, Shaoxing, Zhejiang 312000, P.R. China
E-mail: dxj9666@163.com

Key words: bioinformatics, breast cancer, differentially expressed gene, *NUF2*, prognosis

were then analyzed. In addition, the prognostic value of *NUF2* was analyzed using individual and pooled methods. In a gene set enrichment analysis (GSEA), it was demonstrated that *NUF2* might be involved in cell-cycle related pathways. The results of the present study suggest that *NUF2* is a prognostic indicator of BC.

Materials and methods

Microarray data. GSE42568 (14), GSE45827 (15), GSE65194 (16) and TCGA BC microarray datasets, downloaded from GEO (17) and TCGA (18), were used to screen DEGs in BC. The TCGA dataset was used for analyses of clinical pathological characteristics associated with *NUF2* in patients with BC. The following 5 additional BC microarray datasets were selected for prognostic analyses: GSE1456 (19), GSE22220 (20), NKI (21), GSE4299 (22) and GSE20685 (23). To normalize mRNA levels, patients for each dataset were reclassified into four subsets (X1, X2, X3 and X4) based on the quartile for expression values. The datasets were then reclassified into a new dataset for a pooled analysis.

DEG identification. BC-related microarray data downloaded from the GEO and TCGA databases were processed using R software (version 3.4.3; <https://cran.r-project.org/>). DEGs between BC tissues and normal breast tissues were identified using the limma package in R. Fold-change (FC) values were calculated and the DEGs were further selected based on the following cutoff criteria: $P < 0.01$ and $\log_2 |\text{FC}| > 2$. Overlapping DEGs among the four datasets were identified using Funrich (version 3.1.3; <http://www.funrich.org>).

Functional and pathway enrichment analyses of DEGs. Gene Ontology (GO) is used to identify enriched functions of genes in three independent categories: Biological process (BP), molecular function (MF) and cellular component (CC) (24). Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to identify relevant pathways for the genes (25). GO BP and KEGG signaling pathway analyses of the DEGs were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID) online tool (<https://david.ncifcrf.gov/>) (26) with $P < 0.05$ as the threshold for significance.

Protein-protein interaction (PPI) network analysis. The Search Tool for the Retrieval of Interacting Genes (STRING; <https://string-db.org/>) was used to develop a PPI network. Using the STRING database, DEGs with a combined score ≥ 0.4 were chosen to construct the network, which was visualized using Cytoscape (version 3.6.1) (27). Molecular Complex Detection (MCODE), a plugin for Cytoscape, was used to construct functional modules in the PPI network.

Gene set enrichment analysis (GSEA). A GSEA was conducted based on protocols obtained from the website (<http://software.broadinstitute.org/gsea/index.jsp>) and a previous study (28). GSEA (version 3.0) was run for the KEGG gene sets (c2.cp.kegg.v6.0.symbols.gmt). The number of permutations was set to 1,000 and the phenotype labels were *NUF2*-high and *NUF2*-low. FDR < 0.25 and NOM $P < 0.05$ indicated statistical significance.

Oncomine analysis. Oncomine (<https://www.oncomine.org/>) is an online cancer microarray database, aiming to facilitate the discovery of novel biomarkers from genome-wide expression analyses. In the present study, the mRNA expression differences of *NUF2* between BC and normal breast tissues were explored using the Oncomine database.

Patients and samples. BC and matched adjacent tissues were collected from the Pathology Department of Shaoxing People's Hospital (Shaoxing, China). Samples were obtained from 42 patients at initial diagnosis and were immediately frozen in liquid nitrogen. The present study was authorized by the Hospital Ethics Committee and informed consent was obtained from all patients.

Reverse transcription (RT)-quantitative (q)PCR. Total RNA was isolated from the BC and matched adjacent tissues using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The Nanodrop 2000 (Thermo Fisher Scientific, Inc.) was used to detect the purity and concentration of the total RNA. According to the manufacturer's protocol, RT-qPCR was performed using the LightCycler[®] 480 PCR apparatus (Roche Diagnostics, Basel, Switzerland) and the One Step SYBR[®] PrimeScript[™] RT-PCR kit II (Takara Bio, Inc., Otsu, Japan). Amplification was performed under the following conditions: 42°C for 5 min, 95°C for 10 sec; 40 cycles of 95°C for 5 sec and 60°C for 20 sec; and 65°C for 15 sec. The primers used were as follows: *NUF2* forward primer 5'-TACCATTTCAGCAATT TAGTTACT-3' and reverse primer 5'-TAGAATATCAGCAGT CTCAAAG-3'; and β -actin forward primer 5'-CATGTACGT TGCTATCCAGGC-3' and reverse primer 5'-CTCCTTAAT GTCACGCACGAT-3'. The relative levels of *NUF2* expression were evaluated by the $2^{-\Delta\Delta C_q}$ (29) method using β -actin as the control.

Statistical analyses. All statistical analyses were performed using SPSS 20.0 (IBM Corps., Armonk, NY, USA). An independent t-test was used for analyzing the continuous data. The χ^2 test and χ^2 test with continuity correction were performed to analyze the association of *NUF2* with clinical pathological characteristics. Bonferroni's post hoc test was used to analyze the clinical pathological characteristics between more than 2 groups. Survival curves were generated by the Kaplan-Meier method and significance was determined using the log-rank test. Bonferroni's post hoc test was used for pairwise comparisons. Multivariable survival analysis was performed using the Cox proportional hazards regression model and significance was determined using the likelihood ratio test. $P < 0.05$ was considered to indicate statistically significant differences, while for Bonferroni's test, $P < 0.05/N$ was considered to indicate statistically significant differences, where N=the number of pairwise comparisons.

Results

Identification of DEGs in BC. DEGs between the BC and normal breast tissues were screened using the GEO and TCGA databases. As shown in Fig. 1A, 1,702, 461, 600 and 337 DEGs were upregulated in the GSE45827, GSE42568, GSE65194, and TCGA datasets, and 613, 715, 264, and




Figure 1. Identification of DEGs in breast cancer microarray datasets. In total, (A) 65 DEGs were upregulated and (B) 125 DEGs were downregulated in the intersection of the GSE45827, GSE42568, GSE65194, and TCGA datasets. DEGs, differentially expressed genes; TCGA, the Cancer Genome Atlas.




Figure 2. GO BP analysis and KEGG signaling pathway analysis of DEGs in breast cancer. GO BP analysis of (A) upregulated and (B) downregulated DEGs. KEGG signaling pathway enrichment analysis of (C) upregulated and (D) downregulated DEGs. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto encyclopedia of genes and genomes; ECM, extracellular matrix.

872 DEGs were downregulated, respectively (Fig. 1B). In total, 190 DEGs exhibited the same expression trends in all datasets, including 65 upregulated and 125 downregulated genes.

Functional and pathway enrichment for the DEGs. GO BP and KEGG signaling pathway analyses of the DEGs were performed using DAVID. The upregulated DEGs were mainly enriched for the BP terms cell division, mitotic nuclear division and G2/M transition of mitotic cell cycle (Fig. 2A), while downregulated DEGs were significantly associated with lipid metabolic process, cholesterol homeostasis, and glucose metabolic process (Fig. 2B). Additionally, seven KEGG

pathways were identified for the upregulated genes, including the p53 signaling pathway, cell cycle and extracellular matrix (ECM)-receptor interaction (Fig. 2C). The peroxisome proliferator-activated receptor (PPAR) signaling pathway, AMP-activated protein kinase (AMPK) signaling pathway and proximal tubule bicarbonate reclamation were associated with the downregulated DEGs (Fig. 2D). The detailed results are presented in Table I.

PPI network analysis and the selection of NUF2. Protein interactions often play important roles in cancer progression. A PPI network analysis was performed using the STRING database and Cytoscape. The PPI network was constructed

Table I. Significantly enriched GO biological process terms and KEGG pathways.

A, Upregulated			
Terms	Description	Number of genes	P-value
GO Terms			
GO:0051301	Cell division	18	1.02×10^{-14}
GO:0007067	Mitotic nuclear division	16	1.90×10^{-14}
GO:0000086	G2/M transition of mitotic cell cycle	9	4.82×10^{-08}
GO:0031145	Anaphase-promoting complex-dependent catabolic process	7	5.40×10^{-07}
GO:0042787	Protein ubiquitination involved in Ubiquitin-dependent protein catabolic process	8	1.83×10^{-06}
GO:0007062	Sister chromatid cohesion	7	2.58×10^{-06}
GO:0030574	Collagen catabolic process	6	4.40×10^{-06}
GO:0008283	Cell proliferation	9	7.20×10^{-05}
GO:0051439	Regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle	4	8.86×10^{-05}
GO:0035987	Endodermal cell differentiation	4	1.45×10^{-04}
KEGG pathways			
hsa04110	Cell cycle	8	1.17×10^{-06}
hsa04512	ECM-receptor interaction	7	2.33×10^{-06}
hsa04115	p53 signaling pathway	5	0.000237
hsa04114	Oocyte meiosis	5	0.001499
hsa04510	Focal adhesion	5	0.014347
hsa04151	PI3K-Akt signaling pathway	6	0.019962
hsa05200	Pathways in cancer	6	0.032832
B, Downregulated			
Terms	Description	Number of genes	P-value
GO Terms			
GO:0006629	Lipid metabolic process	9	1.32×10^{-05}
GO:0019915	Lipid storage	5	2.06×10^{-05}
GO:0048662	Negative regulation of smooth muscle cell proliferation	5	4.49×10^{-05}
GO:0042632	Cholesterol homeostasis	6	7.95×10^{-05}
GO:0008217	Regulation of blood pressure	6	8.56×10^{-05}
GO:0006006	Glucose metabolic process	6	9.90×10^{-05}
GO:0019433	Triglyceride catabolic process	4	6.61×10^{-04}
GO:0042593	Glucose homeostasis	6	6.74×10^{-04}
GO:0019432	Triglyceride biosynthetic process	4	7.44×10^{-04}
GO:0001523	Retinoid metabolic process	5	8.33×10^{-04}
KEGG pathways			
hsa03320	PPAR signaling pathway	9	1.14×10^{-07}
hsa04152	AMPK signaling pathway	7	7.34×10^{-04}
hsa04964	Proximal tubule bicarbonate reclamation	4	0.001072
hsa04923	Regulation of lipolysis in adipocytes	5	0.001523
hsa00982	Drug metabolism-cytochrome P450	5	0.003116
hsa04920	Adipocytokine signaling pathway	5	0.003462
hsa00350	Tyrosine metabolism	4	0.00367
hsa00561	Glycerolipid metabolism	4	0.014956
hsa00980	Metabolism of xenobiotics by cytochrome P450	4	0.028412
hsa05205	Proteoglycans in cancer	6	0.033006

KEGG, Kyoto Encyclopedia of genes and genomes; GO, Gene Ontology.




Figure 3. PPI network analysis of DEGs. (A) PPI network containing 149 nodes and 930 edges. (B) Module 1 consisted of 35 nodes and 573 edges, as identified by the MCODE plugin in Cytoscape. (C) Module 2 consisted of 21 nodes and 104 edges, as identified by the MCODE plugin in Cytoscape. Blue nodes represent downregulated genes in BC tissues; red nodes represent upregulated genes in BC tissues. PPI, protein-protein interaction; DEG, differentially expressed genes; BC, breast cancer; MCODE, Molecular Complex Detection.

using 149 DEGs (57 upregulated and 92 downregulated DEGs) with combined scores ≥ 0.4 , and contained 149 nodes and 930 edges (Fig. 3A). A total of two functional modules were identified using the MCODE plugin. Module 1 consisted of 35 nodes and 573 edges including *NUF2*, *TOP2A*, *ASPM*, and *CCNB1* (Fig. 3B). Module 2 included 21 nodes and 104 edges including *COL1A1*, *MMPI*, *MMP9*, and *LPL* (Fig. 3C). Based on the degree of importance, module 1 was chosen for further analysis.

The 35 genes in module 1 were ranked based on log IFCI values in the TCGA database and selected the top 10 hub genes for further analysis. The expression levels of the 10 hub genes

in the BC tissues were >10 -fold ($\log |\text{FC}| \geq 3.42$) increased compared with those in the normal breast tissues. Through literature mining, it was identified that *UBE2C*, *ASPM*, *BIRC5*, *TOP2A*, *KIF20A*, *CEP55*, *TPX2*, *NEK2* and *ANLN*, but not *NUF2*, have been reported extensively in BC-related studies. Therefore, *NUF2* was selected as the focus of subsequent analyses.

***NUF2* expression in BC.** The expression of *NUF2* mRNA in the BC tissues was evaluated using Oncomine (<https://www.oncomine.org/>) (30). The results indicated that the *NUF2* expression level is significantly increased in the BC tissues




Figure 4. Expression of *NUF2* in BC. (A) *NUF2* mRNA was overexpressed in human BC tissues compared with normal breast tissues in the TCGA, (B) Curtis and (C) Richardson microarray databases, as evaluated by Oncomine analysis. (D) *NUF2* mRNA expression was increased in most BC lesions compared with para-carcinoma tissues, as determined by reverse transcription-quantitative PCR. ***P < 0.001. BC, breast cancer; *NUF2*, NDC80 kinetochore complex component.

compared with in the normal breast tissues (P < 0.01; Fig. 4A-C). To further verify these results, 42 pairs of BC tissues and adjacent tissues were analyzed by RT-qPCR. Consistent with the results of the database analysis, the expression of *NUF2* mRNA in the BC tissues was significantly increased (P < 0.001) compared with in the adjacent tissues (Fig. 4D).

Association of *NUF2* with clinical pathological characteristics and survival of patients with BC. To further validate the clinical value of *NUF2*, the association between its expression and the clinical pathological characteristics of the 42 patients with BC recruited from Shaoxing People's Hospital were assessed. The expression of *NUF2* was only significantly associated with age (P < 0.05). Using the data in the TCGA database (contains data on 1,090 patients with BC), *NUF2* expression was found to be significantly associated with age (P < 0.001), estrogen receptor (ER) status (P < 0.001), progesterone receptor (PR) status (P < 0.001), histological type (P < 0.001), TNM stage (P < 0.05), and molecular subtype (P < 0.001). The results are shown in Tables II and III. Furthermore, the clinical pathological characteristics that have multiple groups (>2) need a post hoc test to determine exactly what groups exhibit a difference. Therefore,

Bonferroni's post hoc test was used for pairwise comparison. The results showed that *NUF2* expression is statistically different between TNM stage 1 and 2 (P < 0.01), and tumor stage T1 and T2 (P < 0.001). In terms of molecular subtype, *NUF2* expression was also significantly different in all pairwise comparisons (P < 0.001) except between luminal A and normal-like, and luminal B and basal-like. The detailed results are shown in Tables IV and V.

Furthermore, to elucidate the correlation between the expression of *NUF2* and patient survival, 5 GEO datasets were used. Samples from each dataset were reclassified into four subsets (X1, X2, X3 and X4) according to the quartile of *NUF2* expression. The X1 subset was set with the lowest expression as the reference to calculate the hazard ratio (HR). Each dataset was analyzed by Kaplan-Meier analysis and Cox proportional hazard analysis. High *NUF2* expression was associated with shorter overall survival (OS) and progression-free survival (PFS) compared with low *NUF2* expression in the GSE1456 dataset (Fig. 5A and B) and NKI dataset (Fig. 5C and D). Similar results were obtained in the GEO pooled analysis, as shown in Fig. 5E and F. Based on a further GEO pooled analysis, it was demonstrated that *NUF2* expression levels are significantly associated with poor OS

Table II. Association of *NUF2* with clinical pathological characteristics of breast cancer patients from Shaoxing People's Hospital.

Pathological characteristics	Number of patients (%)	<i>NUF2</i> (%)		P-value ^a
		Low	High	
Age				0.031
<60	21 (50.0)	14 (66.7)	7 (33.3)	
≥60	21 (50.0)	7 (33.3)	14 (66.7)	
HER2 status				0.05
Positive	14 (33.3)	10 (71.4)	4 (29.6)	
Negative	28 (66.7)	11 (39.3)	17 (60.7)	
ER status				0.679 ^b
Positive	35 (83.3)	17 (48.6)	18 (51.4)	
Negative	7 (16.7)	4 (57.1)	3 (42.9)	
PR status				0.107
Positive	27 (64.3)	11 (40.7)	16 (59.3)	
Negative	15 (35.7)	10 (66.7)	5 (33.3)	
TNM stage				0.751
1	12 (28.6)	5 (41.7)	7 (58.3)	
2	25 (59.5)	13 (52.0)	12 (48.0)	
3	5 (11.9)	3 (60.0)	2 (40.0)	
Tumor stage				0.333
T1	19 (45.2)	8 (42.1)	11 (57.9)	
T2	22 (52.4)	13 (59.1)	9 (40.9)	
T3	1 (2.4)	0 (0.0)	1 (100.0)	
Lymph node stage				0.946
N0	27 (64.3)	13 (48.1)	14 (51.9)	
N1	10 (23.8)	5 (50.0)	5 (50.0)	
N2	3 (7.1)	2 (66.7)	1 (33.3)	
N3	2 (4.3)	1 (50.0)	1 (50.0)	
Node metastasis				0.533
Yes	18 (42.9)	10 (55.6)	8 (44.4)	
No	24 (57.1)	11 (45.8)	13 (54.2)	

^aUnless otherwise noted, χ^2 tests were used for comparisons between groups. ^b χ^2 test with continuity correction was used. ER, estrogen receptor; PR, progesterone receptor; TNM, tumor node metastasis; *NUF2*, NDC80 kinetochore complex component.

and PFS in both ER-positive ($P < 0.01$; Fig. 6A and B) and ER-negative ($P < 0.01$; Fig. 6C and D) BC, and the association is more obvious in ER-positive BC. The results of Cox proportional hazards analysis are shown in Table VII. In addition, the results of the Bonferroni's post hoc tests used to compare the Kaplan-Meier survival curves corresponding to >2 groups are shown in Table VI. These results indicated that *NUF2* might be a prognostic factor for BC.

Signaling pathways associated with *NUF2*. Single-gene differential expression analyses in the study of biological processes are limited (28). To effectively reveal the biological significance of microarray datasets, a GSEA was performed to predict gene sets and signaling pathways associated with *NUF2* using the data obtained from the TCGA database. As shown in Fig. 7A-C, *NUF2* may function in cell cycle-related pathways, including the cell cycle, DNA replication, and *p53* signaling pathway.

Discussion

BC is the most common malignant tumor in women, accounting for 25% of female tumors (3). Despite advanced treatment techniques, BC remains the leading cause of death among women (31). Therefore, there is a pressing need for more effective molecular biomarkers to prevent, diagnose, and treat BC. With the development of microarray technology, hundreds of molecules have been found to be abnormally expressed during breast carcinogenesis and progression. The TCGA and GEO databases provide a large number of publicly available microarray datasets for biomarker identification.

In this study, 190 DEGs with the same expression trends were identified in four datasets, and a GO BP analysis showed that the upregulated DEGs were mainly enriched in the biological processes of cell division, mitotic nuclear division, and G2/M transition of mitotic cell cycle, while the downregulated DEGs

Table III. Association of *NUF2* with clinical pathological characteristics of breast cancer patients derived from TCGA database.

Pathological characteristics	Number of patients (%)	<i>NUF2</i> (%)		P-value ^a
		Low	High	
Age				<0.001
<60	579 (53.2)	255 (44.0)	324 (66.0)	
≥60	510 (46.8)	289 (56.7)	221 (43.3)	
HER2 status				0.296
Positive	90 (21.4)	39 (43.3)	51 (56.7)	
Negative	331 (78.6)	164 (49.5)	167 (50.5)	
ER status				<0.001
Positive	803 (77.2)	467 (58.2)	336 (41.8)	
Negative	237 (22.8)	60 (25.3)	177 (74.7)	
PR status				<0.001
Positive	694 (66.9)	415 (60.0)	279 (40.0)	
Negative	343 (33.1)	110 (32.1)	233 (67.9)	
Histology type				<0.001
IDC	779 (79.3)	326 (41.8)	453 (58.2)	
ILC	203 (20.7)	156 (76.8)	47 (23.2)	
TNM stage				0.032
1	181 (17.0)	108 (59.7)	73 (40.3)	
2	619 (58.0)	293 (47.3)	326 (52.7)	
3	247 (23.1)	119 (48.2)	128 (51.8)	
4	20 (1.9)	10 (50.0)	10 (50.0)	
Tumor stage				<0.001
T1	279 (25.7)	171 (61.3)	108 (38.7)	
T2	631 (58.0)	283 (44.8)	348 (55.2)	
T3	137 (12.6)	71 (51.8)	66 (48.2)	
T4	40 (3.7)	19 (47.5)	21 (52.5)	
Lymph node stage				0.095
N0	514 (48.0)	255 (49.6)	259 (50.4)	
N1	360 (33.6)	185 (51.4)	175 (48.6)	
N2	120 (11.2)	48 (40.0)	72 (60.0)	
N3	76 (7.2)	43 (56.6)	33 (43.4)	
Metastasis stage				0.82
M0	906 (97.6)	434 (47.9)	472 (52.1)	
M1	22 (2.4)	10 (45.5)	12 (54.5)	
Molecular subtype				<0.001
Luminal A	419 (0.5)	305 (72.8)	114 (27.2)	
Luminal B	190 (0.23)	26 (13.7)	164 (86.3)	
HER2+	67 (0.08)	26 (38.8)	41 (61.2)	
Basal-like	139 (0.16)	14 (10.1)	125 (89.9)	
Normal-like	23 (0.03)	21 (91.3)	2 (8.7)	

^a χ^2 tests were used for comparisons between groups. TNM, tumor node metastasis; ER, estrogen receptor; PR, progesterone receptor; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; *NUF2*, NDC80 kinetochore complex component.

were related to lipid metabolic process, cholesterol homeostasis, and glucose metabolic process. Cell division and cell cycle are the basic processes in cell proliferation, and their abnormalities contribute to carcinogenesis and tumor progression (32).

Furthermore, the activation of key regulators of lipid and cholesterol metabolism drives the estrogen-independent growth of invasive lobular breast carcinoma cells (33). A KEGG signaling pathway analysis of the DEGs in this study revealed

Table IV. Comparison of clinical pathological characteristics of breast cancer patients from Shaoxing People's Hospital among multiple groups.

Pathological characteristics	Pairwise comparisons (P-values)			
TNM stage	1	2	3	
1	N/A	0.556	0.620	
2	0.556	N/A	1.000	
3	0.620	1.000	N/A	
Tumor stage	T1	T2	T3	
T1	N/A	0.278	1.000	
T2	0.278	N/A	0.435	
T3	1.000	0.435	N/A	
Lymph node stage	N0	N1	N2	N3
N0	N/A	1.000	1.000	1.000
N1	1.000	N/A	1.000	1.000
N2	1.000	1.000	N/A	1.000
N3	1.000	1.000	1.000	N/A

P<0.05/N was considered statistically significant, where N was the number of pairwise comparisons. TNM, tumor node metastasis.

Table V. Comparison of clinical pathological characteristics of breast cancer patients in The Cancer Genome Atlas database among multiple groups.

Pathological characteristics	Pairwise comparisons (P-values)				
TNM stage	1	2	3	4	
1	N/A	0.004 ^a	0.019	0.405	
2	0.004 ^a	N/A	0.822	0.814	
3	0.019	0.822	N/A	0.875	
4	0.405	0.814	0.875	N/A	
Tumor stage	T1	T2	T3	T4	
T1	N/A	0.000 ^a	0.066	0.097	
T2	0.000 ^a	N/A	0.138	0.744	
T3	0.066	0.138	N/A	0.630	
T4	0.097	0.744	0.630	N/A	
Lymph node stage	N0	N1	N2	N3	
N0	N/A	0.605	0.058	0.257	
N1	0.605	N/A	0.031	0.410	
N2	0.058	0.031	N/A	0.023	
N3	0.257	0.410	0.023	N/A	
Molecular subtype	Luminal A	Luminal B	HER2+	Basal-like	Normal-like
Luminal A	N/A	0.000 ^a	0.000 ^a	0.000 ^a	0.049
Luminal B	0.000 ^a	N/A	0.000 ^a	0.322	0.000 ^a
HER2+	0.000 ^a	0.000 ^a	N/A	0.000 ^a	0.000 ^a
Basal-like	0.000 ^a	0.322	0.000 ^a	N/A	0.000 ^a
Normal-like	0.049	0.000 ^a	0.000 ^a	0.000 ^a	N/A

P<0.05/N was considered statistically significant, where N was the number of pairwise comparisons. ^aP<0.05/N. TNM, tumor, node and metastasis.

the importance of the cell cycle, ECM-receptor interaction, PPAR signaling pathway, and AMPK signaling pathway in

BC. Previous studies have reported that ECM could regulate tissue homeostasis, and its dysregulation could promote tumor

Table VI. Comparison of Kaplan-Meier curves among multiple groups.

Datasets		Pairwise comparisons (P-values)			
GSE1456 OS	Subsets	X1	X2	X3	X4
	X1	N/A	0.088	0.008 ^a	0.003 ^a
	X2	0.088	N/A	0.356	0.253
	X3	0.008 ^a	0.356	N/A	0.851
	X4	0.003 ^a	0.253	0.851	N/A
GSE1456 PFS	Subsets	X1	X2	X3	X4
	X1	N/A	0.259	0.002 ^a	0.004 ^a
	X2	0.259	N/A	0.044	0.068
	X3	0.002 ^a	0.044	N/A	0.800
	X4	0.004 ^a	0.068	0.800	N/A
NKI OS	Subsets	X1	X2	X3	X4
	X1	N/A	0.036	0.000 ^a	0.000 ^a
	X2	0.036	N/A	0.113	0.041
	X3	0.000 ^a	0.113	N/A	0.663
	X4	0.000 ^a	0.041	0.663	N/A
NKI PFS	Subsets	X1	X2	X3	X4
	X1	N/A	0.361	0.002 ^a	0.003 ^a
	X2	0.361	N/A	0.034	0.057
	X3	0.002 ^a	0.034	N/A	0.840
	X4	0.003 ^a	0.057	0.840	N/A
GEO pooled OS	Subsets	X1	X2	X3	X4
	X1	N/A	0.007 ^a	0.000 ^a	0.000 ^a
	X2	0.007 ^a	N/A	0.063	0.017
	X3	0.000 ^a	0.063	N/A	0.630
	X4	0.000 ^a	0.017	0.630	N/A
GEO pooled PFS	Subsets	X1	X2	X3	X4
	X1	N/A	0.027	0.000 ^a	0.000 ^a
	X2	0.027	N/A	0.010	0.002 ^a
	X3	0.000 ^a	0.010	N/A	0.639
	X4	0.000 ^a	0.002 ^a	0.639	N/A
GEO pooled ER(+) OS	Subsets	X1	X2	X3	X4
	X1	N/A	0.006 ^a	0.000 ^a	0.000 ^a
	X2	0.006 ^a	N/A	0.307	0.314
	X3	0.000 ^a	0.307	N/A	0.925
	X4	0.000 ^a	0.314	0.925	N/A
GEO pooled ER(+) PFS	Subsets	X1	X2	X3	X4
	X1	N/A	0.197	0.000 ^a	0.001 ^a
	X2	0.197	N/A	0.022	0.065
	X3	0.000 ^a	0.022	N/A	0.730
	X4	0.001 ^a	0.065	0.730	N/A
GEO pooled ER(-) OS	Subsets	X1	X2	X3	X4
	X1	N/A	0.495	0.031	0.016
	X2	0.495	N/A	0.079	0.028
	X3	0.031	0.079	N/A	0.762
	X4	0.016	0.028	0.762	N/A
GEO pooled ER(-) PFS	Subsets	X1	X2	X3	X4
	X1	N/A	0.679	0.029	0.055
	X2	0.679	N/A	0.095	0.106
	X3	0.029	0.095	N/A	0.834
	X4	0.055	0.106	0.834	N/A

P<0.05/N was considered statistically significant, where N was the number of pairwise comparisons. ^aP<0.05/N. OS, overall survival; PFS, progression-free survival; ER, estrogen receptor.




Figure 5. Role of *NUF2* in the prognosis of BC patients. (A) *NUF2* expression was significantly associated with OS of BC patients in the GSE1456 dataset, (C) NKI dataset, and (E) GEO pooled dataset. *NUF2* expression was significantly associated with PFS of BC patients in the (B) GSE1456 dataset, (D) NKI dataset and (F) GEO pooled dataset. GEO, gene expression omnibus; BC, breast cancer; OS, overall survival; PFS, progression free survival; ER, estrogen receptor; PR, progesterone receptor; *NUF2*, NDC80 kinetochore complex component.

progression by affecting adhesion, migration, differentiation, proliferation, and apoptosis of tumor cells (34,35). In addition, an increase in the rigidity of the ECM due to the local accumulation of crosslinked collagen matrix is associated with cancer progression (36). Yao *et al* (37) found that the PPAR signaling pathway is involved in breast carcinogenesis. Song *et al* (38) suggested that activation of the AMPK signaling pathway may be beneficial for the promotion of tumor necrosis factor-related apoptosis-inducing ligand-mediated anti-BC treatment. a PPI network was constructed in this study and two functional modules were identified. According to the MCODE scores, which represent importance, module 1 was found to play a major role in the PPI network. By combining the log |FC| values of the DEGs in the TCGA database and literature mining, *NUF2* was selected for further research as a key gene in BC.

Although Xiang *et al* (12) found that *NUF2* is upregulated in BC, using cDNA microarray data of BC patients, further experiments have not been performed to verify this finding. In this

study, by Oncomine analysis and RT-qPCR assay, it was verified that *NUF2* is overexpressed in BC tissues, further confirming the results obtained by data mining. Shiraishi *et al* (39) found that *NUF2* expression is significantly associated with prostate cancer recurrence, and patients with high *NUF2* expression have significantly shorter survival times without biochemical recurrence. Hu *et al* (10) showed that the overexpression of *NUF2* could be related to poor prognosis in pancreatic cancer. Zhang *et al* (13) found that *NUF2* expression has prognostic values for BC patients, by simply using the BC-GenExMiner online analysis tool. However, further analysis has not been conducted. To this end, the present study analyzed the precise roles and underlying molecular mechanisms of *NUF2* in BC. By stratified analysis and pooled analysis of five GEO datasets, it was found that patients with BC and high *NUF2* expression had worse prognosis than patients with low *NUF2* expression in both ER-positive and ER-negative BC. Using clinical data for 42 patients, it was demonstrated that *NUF2* expression was only associated with




Figure 6. Prognostic value of *NUF2* in ER-positive and ER-negative BC. Association of *NUF2* expression with (A) OS and (B) PFS in ER-positive BC in the GEO pooled dataset. Association of *NUF2* expression with (C) OS and (D) PFS in ER-negative BC in the GEO pooled dataset. GEO, gene expression omnibus; BC, breast cancer; OS, overall survival; PFS, progression free survival; ER, estrogen receptor; PR, progesterone receptor; *NUF2*, NDC80 kinetochore complex component.




Figure 7. Signaling pathways associated with *NDC80* kinetochore complex component predicted by gene set enrichment analysis. (A) Cell cycle ($P=0.000$; $FDR=0.000$; $ES=0.72$). (B) DNA replication ($P<0.001$; $FDR<0.001$; $ES=0.84$). (C) *p53* signaling pathway ($P=0.000$; $FDR=0.004$; $ES=0.51$). FDR , false discovery rate; KEGG, Kyoto Encyclopedia of genes and genomes; ES , enrichment score.

age. Small sample size, erroneous tissue sampling, RNA degradation, and fluctuating efficiency of RT-qPCR may affect the results of the analysis. This hypothesis can be tested through the following methods: Increasing sample size, determining the type of tissue with pathological examination, detecting RNA degradation by RNA electrophoresis, and verifying amplification efficiency of RT-qPCR by the standard curve method. The lack of additional experiments to test these possibilities is a limitation to the present study. Therefore, the relationship was further analyzed using clinical data for patients with BC in the TCGA database. The expression of *NUF2* was positively correlated with

tumor stage and negatively correlated with ER status, consistent with the results from a number of studies showing that advanced tumors and ER-negative tumors are probably related to poor survival (40-42), suggesting that *NUF2* plays an important role in tumor progression and prognosis. To elucidate the molecular mechanisms by which *NUF2* mediates breast carcinogenesis and progression, GSEA was performed in this study. The results revealed that *NUF2* is involved in cell cycle-related pathways.

In conclusion, the present data analysis and RT-qPCR validation indicated that *NUF2* is highly expressed in BC and is associated with its multiple pathological features and prognosis.

Table VII. Univariate and multivariate analyses of NUF2 and survival in GEO datasets.

Dataset	Overall survival		Progression-free survival	
	HR (95% CI)	Adjusted HR (95% CI)	HR (95% CI)	Adjusted HR (95% CI)
GSE1456				
X1	Reference	Reference	Reference	Reference
X2	3.94 (0.82-18.95)	3.66 (0.75-17.75)	2.19 (0.55-8.74)	1.99 (0.49-8.05)
X3	6.18 (1.37-27.90) ^a	4.6 (0.91-23.28)	5.7 (1.64-19.83) ^b	3.94 (1.00-15.45) ^a
X4	6.69 (1.50-29.91) ^a	5.11 (1.03-25.24) ^a	5.21 (1.48-18.29) ^b	3.76 (0.97-14.57)
GSE22220				
X1	N/A	N/A	Reference	Reference
X2	N/A	N/A	2.05 (0.95-4.43)	1.69 (0.77-3.69)
X3	N/A	N/A	2.31 (1.07-4.96) ^a	1.79 (0.82-3.92)
X4	N/A	N/A	3.34 (1.60-6.95) ^b	2.30 (1.05-5.02) ^a
NKI dataset				
X1	Reference	Reference	Reference	Reference
X2	2.39 (1.04-5.51) ^a	2.01 (0.87-4.68)	1.35 (0.72-2.54)	1.29 (0.68-2.46)
X3	3.97 (1.80-8.77) ^b	2.88 (1.28-6.48) ^a	2.39 (1.33-4.30) ^b	1.97 (1.07-3.61) ^a
X4	4.48 (2.03-9.89) ^c	2.63 (1.13-6.12) ^a	2.31 (1.27-4.21) ^b	1.84 (0.96-3.52)
GSE4299				
X1	N/A	N/A	Reference	Reference
X2	N/A	N/A	1.95 (0.99-3.85)	1.93 (0.97-3.81)
X3	N/A	N/A	2.16 (1.09-4.27) ^a	2.13 (1.07-4.24) ^a
X4	N/A	N/A	2.11 (1.07-4.17) ^a	2.09 (1.04-4.19) ^a
GSE20685				
X1	Reference	Reference	Reference	Reference
X2	1.11 (0.57-2.14)	1.1 (0.57-2.14)	1.17 (0.67-2.05)	1.16 (0.66-2.03)
X3	1.58 (0.85-2.95)	1.58 (0.85-2.95)	1.12 (0.64-1.98)	1.13 (0.64-2.00)
X4	1.59 (0.85-2.96)	1.58 (0.84-2.97)	1.46 (0.84-2.52)	1.42 (0.82-2.48)
GEO pooled				
X1	Reference	Reference	Reference	Reference
X2	2.69 (1.29-5.60) ^b	2.18 (1.04-4.57) ^a	1.67 (1.05-2.65) ^a	1.5 (0.95-2.39)
X3	4.43 (2.20-8.91) ^c	3 (1.46-6.15) ^b	2.72 (1.77-4.19) ^c	2.13 (1.36-3.32) ^b
X4	4.94 (2.46-9.92) ^c	2.87 (1.38-5.94) ^b	2.98 (1.94-4.59) ^c	2.1 (1.33-3.32) ^b
GEO pooled ER(+)				
X1	Reference	Reference	Reference	Reference
X2	3.84 (1.41-10.48) ^b	3.23 (1.18-8.88) ^a	1.57 (0.79-3.13)	1.39 (0.70-2.79)
X3	5.48 (2.08-14.49) ^b	3.93 (1.46-10.61) ^b	3.03 (1.62-5.69) ^b	2.32 (1.22-4.44) ^a
X4	5.60 (2.06-15.23) ^b	3.74 (1.34-10.46) ^a	2.83 (1.45-5.52) ^b	2.09 (1.04-4.16) ^a
GEO pooled ER(-)				
X1	Reference	Reference	Reference	Reference
X2	1.40 (0.46-4.20)	1.19 (0.39-3.61)	1.28 (0.46-3.62)	1.09 (0.38-3.11)
X3	2.96 (1.07-8.20) ^a	1.88 (0.65-5.45)	2.60 (1.01-6.72) ^a	1.58 (0.58-4.34)
X4	3.23 (1.22-8.54) ^a	1.96 (0.70-5.52)	2.44 (0.97-6.10)	1.46 (0.54-3.91)

For multivariate analysis, HR was adjusted by ER status and Elston grade in GSE1456. In GSE22220, HR was adjusted by age and Elston grade. In NKI and GSE4299, HR was adjusted by age, Elston grade, and ER status. For GSE20685, HR was adjusted by age. HR was adjusted by ER status and Elston grade in the pooled analysis. For GEO pooled ER(+) and GEO pooled ER(-), HR was adjusted by Elston grade. ^aP<0.05, ^bP<0.01 and ^cP<0.001 vs. the X1 group. HR, hazard ratio; ER, estrogen receptor; GEO, gene expression omnibus; CI, confidence interval.

NUF2 is therefore a potential therapeutic target and prognostic indicator of BC. However, this study had several limitations.

First, only mRNA data were obtained from the databases and RT-qPCR, and this single-gene-level analysis cannot fully

capture the expression of *NUF2* in BC. Second, experimental validation of the results was not performed. Therefore, further research is required to determine the roles of *NUF2* in BC.

NUF2 is overexpressed in BC and is associated with its multiple pathological features. More importantly, *NUF2* may play an important role in predicting the clinical outcomes of different BC subgroups.

Acknowledgments

Not applicable.

Funding

This study was supported by the Public Technology Research Project of Zhejiang Province (grant no. LGF18H200006) and the Medicines Health Technology Plan Project of Zhejiang Province (grant no. 2018PY073).

Availability of data and materials

The datasets analyzed during the current study are available in the TCGA (<https://cancergenome.nih.gov/>) and GEO (<https://www.ncbi.nlm.nih.gov/geo/>) databases.

Authors' contributions

WJX, YNW, and XJD participated in the study design. WJX, YNW, and XPX contributed to data collection and analysis. WJX, YZW, and SML were involved in the collection of samples and RT-qPCR. All authors were involved in the writing of the article. XJD critically reviewed the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved and supervised by the Ethics Committee of Shaoxing People's Hospital (Shaoxing, China). Written informed consent was obtained from all participants.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. *CA Cancer J Clin* 67: 7-30, 2017.
2. Donepudi MS, Kondapalli K, Amos SJ and Venkanteshan P: Breast cancer statistics and markers. *J Cancer Res Ther* 10: 506-511, 2014.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108, 2015.
4. Tan W, Yang M, Yang H, Zhou F and Shen W: Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. *Cancer Manag Res* 10: 4333-4347, 2018.
5. Salem Y, Yacov N, Propheta-Meirani O, Breitbart E and Mendel I: Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis. *Int J Cancer* 144: 125-135, 2019.
6. Kinsella MD, Nassar A, Siddiqui MT and Cohen C: Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience. *Int J Clin Exp Pathol* 5: 530-536, 2012.
7. Piao J, Chen L, Jin T, Xu M, Quan C and Lin Z: Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker. *Hum Pathol* 73: 33-40, 2018.
8. Sandoo A, Kitas GD and Carmichael AR: Breast cancer therapy and cardiovascular risk: Focus on trastuzumab. *Vasc Health Risk Manag* 11: 223-228, 2015.
9. Nabetani A, Koujin T, Tsutsumi C, Haraguchi T and Hiraoka Y: A conserved protein, Nuf2, is implicated in connecting the centromere to the spindle during chromosome segregation: A link between the kinetochore function and the spindle checkpoint. *Chromosoma* 110: 322-334, 2001.
10. Hu P, Chen X, Sun J, Bie P and Zhang LD: siRNA-mediated knockdown against *NUF2* suppresses pancreatic cancer proliferation in vitro and in vivo. *Biosci Rep* 35: pii: e00170, 2015.
11. Fu HL and Shao L: Silencing of *NUF2* inhibits proliferation of human osteosarcoma Saos-2 cells. *Eur Rev Med Pharmacol Sci* 20: 1071-1079, 2016.
12. Xiang YJ, Fu Q, Ma ZB, Gao DZ, Zhang Q, Li YY, Li L, Liu L, Ye CM, Yu ZG and Guo MM: Screening for candidate genes related to breast cancer with cDNA microarray analysis. *Chronic Dis Transl Med* 1: 65-72, 2015.
13. Zhang W, Mao JH, Zhu W, Jain AK, Liu K, Brown JB and Karpen GH: Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. *Nat Commun* 7: 12619, 2016.
14. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, *et al*: Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis. *Carcinogenesis* 34: 2300-2308, 2013.
15. Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F, Dubois T, Dutreix M, Vincent-Salomon A, Miller KM and Mechta-Grigoriou F: Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. *EMBO Mol Med* 8: 527-549, 2016.
16. Maubant S, Tesson B, Maire V, Ye M, Rigai G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S and Dubois T: Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. *PLoS One* 10: e0122333, 2015.
17. Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, *et al*: Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. *Cancer Res* 74: 3114-3126, 2014.
18. Tomczak K, Czerwińska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. *Contemp Oncol (Pozn)* 19: A68-A77, 2015.
19. Pawitan Y, Bjohle J, Amler L, Borg AL, Eghazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, *et al*: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. *Breast Cancer Res* 7: R953-R964, 2005.
20. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. *Cancer Res* 71: 5635-5645, 2011.
21. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, *et al*: A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 347: 1999-2009, 2002.
22. Jones SB, DePrimo SE, Whitfield ML and Brooks JD: Resveratrol-induced gene expression profiles in human prostate cancer cells. *Cancer Epidemiol Biomarkers Prev* 14: 596-604, 2005.
23. Kao KJ, Chang KM, Hsu HC and Huang AT: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. *BMC Cancer* 11: 143, 2011.
24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, *et al*: Gene ontology: Tool for the unification of biology. The gene ontology consortium. *Nat Genet* 25: 25-29, 2000.

25. Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 28: 27-30, 2000.
26. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. *Genome Biol* 4: P3, 2003.
27. Doerks T, Copley RR, Schultz J, Ponting CP and Bork P: Systematic identification of novel protein domain families associated with nuclear functions. *Genome Res* 12: 47-56, 2002.
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 102: 15545-15550, 2005.
29. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
30. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincaid-Beal C, Kulkarni P, *et al*: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia* 9: 166-180, 2007.
31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
32. Xue D, Cheng P, Han M, Liu X, Xue L, Ye C, Wang K and Huang J: An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer. *OncoTargets Ther* 11: 4755-4768, 2018.
33. Chen L, Yuan L, Qian K, Qian G, Zhu Y, Wu CL, Dan HC, Xiao Y and Wang X: Identification of biomarkers associated with pathological stage and prognosis of clear cell renal cell carcinoma by co-expression network analysis. *Front Physiol* 9: 399, 2018.
34. Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B and Oesterreich S: Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. *Breast Cancer Res* 20: 106, 2018.
35. Kaushik N, Kim S, Suh Y and Lee SJ: Proinvasive extracellular matrix remodeling for tumor progression. *Arch Pharm Res* 42: 40-47, 2019.
36. Walker C, Mojares E and Del Rio Hernández A: Role of extracellular matrix in development and cancer progression. *Int J Mol Sci* 19: pii: E3028, 2018.
37. Tilghman RW, Cowan CR, Mih JD, Koryakina Y, Gioeli D, Slack-Davis JK, Blackman BR, Tschumperlin DJ and Parsons JT: Matrix rigidity regulates cancer cell growth and cellular phenotype. *PLoS One* 5: e12905, 2010.
38. Yao PL, Morales JL, Zhu B, Kang BH, Gonzalez FJ and Peters JM: Activation of peroxisome proliferator-activated receptor- β/δ (PPAR- β/δ) inhibits human breast cancer cell line tumorigenicity. *Mol Cancer Ther* 13: 1008-1017, 2014.
39. Song W, Yan CY, Zhou QQ and Zhen LL: Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. *Biomed Pharmacother* 89: 845-856, 2017.
40. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P and Getzenberg RH: Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. *J Transl Med* 9: 153, 2011.
41. Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X and Giuliano AE: Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. *JAMA Surg* 149: 125-129, 2014.
42. Ryu JM, Choi HJ, Kim I, Lee SK, Yu J, Kim JE, Kang BI, Lee JE, Nam SJ and Kim SW: Only estrogen receptor 'positive' is not enough to predict the prognosis of breast cancer. *Breast Cancer Res Treat* 172: 627-636, 2018.
43. Dunnwald LK, Rossing MA and Li CI: Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. *Breast Cancer Res* 9: R6, 2007.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.